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Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with pulmonary hemorrhage is rare in
childhood. Standard treatment includes corticosteroids and cyclophosphamide (CYC), which is associated with a
high level of toxicity. We report a white female with ANCA positive pulmonary hemorrhage who was treated with
cyclophosphamide (CYC) and rituximab (RTX) combination therapy.
Background
AAV with pulmonary hemorrhage is rare in childhood.
Untreated AAV with pulmonary hemorrhage is associated
with a 2 year mortality rate in excess of 90% [1]. Standard
treatment with a corticosteroid may be associated with
medication related complications. We present a case of
recurrent pulmonary hemorrhage associated with anti-
neutrophil antibody (ANCA)-associated vasculitis (AAV)
in childhood. Treatment with cyclophosphamide (CYC)
and rituximab (RTX) produced a prompt and sustained
remission, and she was able to discontinue steroid therapy.
Case Presentation
BH, a white female, presented at 7 years of age with fever,
cough and respiratory distress following Streptococcal
pharyngitis. Her chest radiograph revealed bilateral pat-
chy infiltrates. She was hospitalized with hypoxemia and
hypercapnea and required intubation and mechanical
ventilation for 14 days. Her endotracheal tube secretions
were noted to be bloody and her hemoglobin fell from
10.6 to 8.5 g/dl within 24 hours following admission. The
Indices of Coagulation were normal and she was negative
for antibodies to anti-nuclear antibody (ANA) and glo-
merular basement membrane; in addition, protease 3 and
myloperoxidase were both negative. There was no hema-
turia, and C-reactive protein (CRP) was elevated at 12.28
mg/dL, 8.66 mg/dL, and 10.11 mg/dL. A tracheal culture
grew Pseudomonas, and chest radiographs showed dif-
fuse airspace opacities with a small right pleural effusion.
She was treated with surfactant and dexamethasone, as
well as epinephrine and helium in the inspired gas and
17 mg of parenteral methylprednisolone every 6 hours
for 14 days. Following a blood transfusion, she slowly sta-
bilized with supportive care and was discharged after
eighteen days. Pulmonary hemorrhage was suspected, but
a bronchoscopy was refused.
One month after discharge, she complained of rhinor-
rhea, congestion, cough, stomach pain, and vomiting.
Three months later, she again had Streptococcal pharyn-
gitis. She underwent an elective bronchoscopy to assess for
residual pulmonary hemorrhage. The bronchoscopy
showed no active bleeding, though subsequently she had
an acute PH episode during the bronchoscopy and again
required mechanical ventilation. There was no hematuria.
Her CRP was 20.40 mg/dL, and she had a positive
Epstein-Barr varius titer of 1:160. Her chest computed
tomography scan revealed bilateral infiltrates (Figure 1).
She was treated with dexamethasone and vasopressors.
She again required a blood transfusion. Her symptoms
improved, and she was discharged on 1 mg/kg daily of
prednisolone after 8 days. * Correspondence: bairdem@hss.edu
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mg daily and subsequently tapered to 7.5 mg every
other day. Chest radiographs continued to show bilateral
patchy infiltrates, and she had periodic hemoptysis. The
reticulocyte count peaked at 5.96 with a hemoglobin of
13.6, 15 months after discharge. Her prednisone dose
was increased to 15 mg daily in response to continued
bilateral infliltrates on radiograph and reticulocytosis.
Almost 3 years later, at 10 years of age, a chest radio-
graph showed worsening diffuse airspace opacities,
pulmonary interstitial emphysema, and a pneumo-medias-
tinum following Streptococcal pharyngitis. She again
required admission and mechanical ventilation for pul-
monary hemorrhage and respiratory failure. During this
admission she tested positive for ANCA Myloperoxidase
antibodies by indirect fluorescent antibody assay at 130
AU/mL and 99 AU/mL (Figure 2), with persistently nega-
tive ANA and anti glomerular basement membrane anti-
body. There was no hematuria. The patient had an
elevated CRP of 11.75 mg/dL during admission. She was
treated with vasopressors and 25 mg of perenteral methyl-
prednisolone every 6 hours. She was intubated for 12 days.
Her symptoms improved, and she was discharged after
nineteen days on prednisolone of 1 mg/kg daily.
Figure 1 CT scan at the carina level of the lung showing
hemorrhage during the second admission.
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Figure 2 Steroid dose and myloperoxidase (MPO) IgG ANCA antibodies over time. The blue line represents prednisolone dose in mg daily,
while the scatter plot shows MPO IgG ANCA antibodies in AU/mL. Month 0 is defined as the first admission for pulmonary hemorrhage. The first
three arrows indicate the hospitalizations for acute pulmonary hemorrhage, and the last three arrows represent the infusions with CYC and RTX.
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Page 2 of 4Because she had recurrent episodes of life threaten-
ing pulmonary hemorrhage despite 3 years of chronic
steroid administration, we elected to treat her aggres-
sively for AAV at 10 years of age. At the time of the
first infusion, she was being treated with 45 mg daily
of prednisolone. After appropriate discussion of the
risks and benefits, consent was obtained and she was
hospitalized for CYC and RTX treatment (750 mg/m
2
of CYC and 600 mg/m
2 of RTX with a maximum of
1000 mg). Following this therapy she was discharged
on prednisolone of 30 mg daily which was tapered off
gradually over five months. Six and eighteen months
after the first infusion, she was retreated with the same
dose of CYC and RTX. She tolerated the treatment
well. There were no recorded infections or leucopenia.
The patient’s CRP and reticulocyte count have normal-
ized; the most recent CRP was 0.53 mg/dL. There have
been no further episodes of pulmonary hemorrhage,
and she remains well without corticosteroid therapy
two years following her last infusion.
Discussion
Diagnosis of AAV was made according to definitions
of the Chapel Hill Consensus Conference. The persis-
tently elevated reticulocyte count prior to CYC/RTX
therapy suggested that our patient’s bleeding was a
chronic process. Conventional treatment for this
chronic condition includes 3 years of CYC and corti-
costeroids [2,3].
RTX has recently been investigated as an alternative
treatment for AAV [4-8], but two recent studies of RTX in
AAV found no clear superiority to CYC [7,9]. The combi-
nation of CYC and RTX has been used in an adult with
pulmonary hemorrhage secondary to SLE [10]., and
we have used it extensively in childhood rheumatic dis-
eases [11-13]. We therefore hypothesized that it might be
helpful in our patient with AAV-associated pulmonary
hemorrhage. This treatment was given to achieve remis-
sion. Alternative therapies of uncertain benefit in this
setting might include plasma exchange [14,15], as well as
azathioprine or mycophenolate mofetil [16].
Conclusions
Our patient’s remission suggests that combination ther-
a p yw i t hC Y Ca n dR T Xm a yb ee f f e c t i v ei nt h i sc o n d i -
tion. Further studies of the efficacy of this therapy in
the treatment of AAV are needed.
Consent
A waiver of informed consent and waiver of Health Insur-
ance Portability and Accountability Act authorization have
been obtained through the local Institutional Review
Board.
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